The UK could emerge from Brexit with a better system for getting innovative new medicines to patients, according to Gilead Sciences’ Gordon Lundie. However, for this to happen, the reviews that England’s health technology appraisal body, NICE, is conducting into its methods and processes must lead to much needed updates on issues including discounting and uncertainty and join up all parts of the access system, said Lundie, Gilead’s senior director of market access and reimbursement in the UK and Ireland.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?